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Objectives: SHIFT examined the effect of adding ivabradine, a heart rate lower-
ing therapy, to optimised standard therapy in chronic heart failure (HF) patients 
(n= 6505). This study reports methods and results for an analysis of SHIFT patient 
quality of life data used to inform the UK cost-effectiveness analysis for ivabra-
dine. MethOds: EQ-5D quality of life data were collected for patients in coun-
tries with a validated questionnaire (n= 5313). EQ-5D data were analysed using 
regression techniques appropriate for repeated observations across individuals 
over time. Results: Ivabradine was associated with a significant gain in patient 
quality of life (utility). Utility values were estimated to range between 0.82-0.46 
[standard care, New York Heart Association (NYHA) class I-IV] and between 0.84-
0.47 (ivabradine, NYHA I-IV). Hospitalisations were strongly associated with a 
reduction in utility, this reduction varied according to NYHA class from -0.07 
(NYHA I) to -0.21 (NYHA IV). Patients with more severe heart failure symptoms 
(NYHA III and IV), were found to suffer a greater loss in utility given a hospi-
talisation than patients with milder symptoms (NYHA I and II). cOnclusiOns: 
Ivabradine was associated with a significant improvement in quality of life. In 
addition, hospitalisation was found to significantly reduce patient quality of life; 
ivabradine is consequently expected to convey further quality of life benefits by 
avoiding the temporary utility loss associated with hospitalisations. Cumulatively, 
over a patient’s life time, this may generate important gains in quality of life for 
ivabradine versus standard care.
PCV124
HealtH OutCOmes at 6 tO 120 mOntHs sinCe Heart transPlant in 
sPain: CliniCal status, HealtH related-Quality Of life and utility 
assessment
Cuervo J.1, Delgado J.F.2, Crespo M.G.3, Crespo M.A.1, Rebollo P.1
1LASER Analytica, Oviedo, Spain, 2Hospital 12 de Octubre, Madrid, Spain, 3Complejo Hospitalario 
A Coruña, A Coruña, Spain
Objectives: To evaluate the outcomes related to heart transplantation in adult 
recipients at 6±1 (Group I),12±2 (Group II), 36±6 (Group III), 60±10 (Group IV) or 120±20 
(Group V) months after receiving the allograft. MethOds: A multicenter, cross-sec-
tional study was conducted in different transplant units from Spain (n= 14). Patients 
(aged > 18 years) with a heart transplant (HTx) due to congestive heart failure and 
living with a single functioning graft were proposed to participate. Clinical status 
was assessed with the New York Heart Association Scale. Besides, participants com-
pleted the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EQ-5D. Other 
measures of social support and caregivers’ burden were also included. Differences 
between groups were studied (Chi-squared, Kruskal-Wallis and Mann-Whitney U 
with Bonferroni correction tests). Multivariate regression analyses were applied to 
examine the association of clinical and socio-demographic variables with question-
naires’ scores. Results: A total of 303 transplant recipients (77.9% males) with a 
mean age(SD) of 56.4(11.4) years were included. High levels of health-related quality 
of life (HRQoL) were found at all stages after transplant. However, a slight decrement 
was detected after 10 years since transplantation (p≤ 0.033). EQ-5D utility mean(SEM) 
scores were: Group I-0.81(0.03)-; Group II-0.82(0.03)-; Group III-0.85(0.03)-; Group 
IV-0.86(0.02)-; Group V-0.75(0.03)--). VAS values (EQ-5D) were close to those of the 
general population, with the exception of patients at 10 years since transplanta-
tion whose scores were lower. Multivariate analyses showed that this decrement 
in well-being was related to comorbid medical conditions, severe vascular disease 
of allograft and the number of hospitalizations (EQ-5D: 48.4% of explained vari-
ance, F4,164= 38.46, p< 0.001; KCCQ-overall functional score-: 45.0% F3,198= 54.073, 
p< 0.001). cOnclusiOns: : HTx outcomes in Spain seem to be satisfactory with 
good achievements in HRQoL and utility scores.
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Objectives: The modified Rankin Scale (mRS) is frequently used in clinical stud-
ies to measure the level of disability following stroke and TIA. As the mRS is a 
disease-specific instrument, it can not be easily translated into preference-based 
utility-weights to be used in cost-effectiveness analyses (CEAs). Data on utility-
weights by the mRS disability level are limited. We estimated the relation between 
mRS scores and utility-weights in a convenience sample of “real-world” stroke 
survivors. MethOds: During a personal interview of 148 community dwelling 
long-term stroke survivors attending day-care rehabilitation centers through-
out Israel, we estimated the level of disability using the mRS, ranging from: no 
symptoms/disability (mRS= 0), to severe disability (mRS= 5). Patients also com-
pleted the EuroQoL (EQ-5D) questionnaire, the most commonly used instrument 
for obtaining utility values. Utility-weights were calculated using the EQ-5D UK 
tariffs. Health states may range from -0.594 to 1, where 1.0 is defined as per-
fect health and zero represents death. Results: Mean age (±SD) of patients was 
65.8±9.8, ranging from 28-85 years, with male predominance of 73.6%. Over 80% 
of patients were married, living with their spouse or family. The vast majority 
(92%) of patients did not work at the time of interview, mainly due to the stroke. 
Mean time from first stroke was 7.2±5.9 years and 1/3 of respondents experienced 
> 1 stroke events. Mean utility-weights (±SD) were as follows: mRS 0-1(N= 31), 
0.748±0.231; mRS 2-3 (N= 78), 0.395±0.317; mRS 4-5 (N= 38), 0.055±0.277. Nineteen 
percent of patients had a utility-weight < 0 representing a health state considered 
worse than death. cOnclusiOns: While utility-weights of stroke survivors with 
no symptoms/no significant disability (mRS 0-1), are comparable to those used 
in published CEAs, patients with moderate and severe disability (mRS 4-5) show 
T-test. Results: From the 855 index patients 375 could be matched to a reference 
patient. Mean adherence rates before the index date were 79% for both groups. 
After the index date, mean adherence rates were 81% for index patients and 71% for 
reference patients (p-value < 0.001). Index patients were more likely to become full-
adherent and less likely to become non-adherent. 26% of the index patients used 
more statins after the event than before whereas 20% used less. cOnclusiOns: 
Patients receiving a statin are likely to become more adherent after the occurrence 
of a cardiovascular event during statin treatment. One in five of these patients, how-
ever, become less adherent showing there are still important health and economic 
benefits to achieve by tailoring the management of individual patients.
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Objectives: New oral anticoagulants (NOACs) have the promise to change the man-
agement of patients with atrial fibrillation (AF), and can be used in lieu of vitamin K 
antagonists (VKAs) or antiplatelet drugs (AP). We aimed to obtain contemporary data 
on the health state of AF patients under everyday practice conditions at the time of 
introduction of NOACs. MethOds: PREFER in AF is a non-interventional study that 
prospectively documents AF patients in terms of clinical characteristics, manage-
ment, quality of life and other outcome parameters. The new EuroQol EQ-5D-5L 
descriptive system was applied in PREFER in AF to obtain patient-reported generic 
health-related quality of life information and utility scores to inform resource allo-
cation decisions. Results: Of the 7243 AF patients (63.1% males, mean age 71.5 ± 
10.7 years), 2159 (30.0%) had paroxysmal, 1731 (24.0%) persistent, 517 (7.2%) long-
standing persistent, and 2793 (38.8%) permanent AF. Comorbidities were highly prev-
alent. On the visual analogue scale, the mean score in 5674 patients (78.3% EQ-5D 
participation rate) was 67.7 ±18.4 points, with no major differences between patients 
on NOACs (68.4), VKAs (67.6), AP (69.7), or VKAs+AP (65.5), respectively. Problems of 
any severity were reported for mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression in 50.1%, 20.7%, 45.0%, 55.4%, and 47.1%. The overall utility 
index was 0.85 ±0.17. The 319 patients on NOACs had the same utility index as the 
182 patients without VKAs or AP (0.80 in both groups), whereas the 2937 patients 
on VKAs, the 342 on AP or the 425 patients on VKAs+AP had lower indices (0.77 vs. 
0.77 vs. 074). cOnclusiOns: Patients with AF present with reduced self-reported 
quality of life compared to the general population. Patients receiving NOACs had 
a slightly higher quality of life, possibly illustrating that this type of treatment 
is initially given to “healthier” populations compared to established VKA therapy.
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Objectives: A systematic review was conducted to determine the quality of life 
(QoL) in patients with venous thromboembolism (VTE). VTE encompasses deep 
vein thrombosis (DVT) and pulmonary embolism (PE) and may be associated with 
long-term complications including post-thrombotic syndrome (PTS) in up to 50% of 
patients following symptomatic DVT. MethOds: Eligible English language studies 
reporting QoL and utility scores for VTE (published since 1990 from any geographical 
location) were identified from electronic databases (Medline, EMBASE and Cochrane 
Library: accessed December 2012) and conference proceedings. Results: Thirty 
studies (VTE= 4; DVT= 23; PE= 3) that were eligible for inclusion were conducted 
in Europe (n= 11), Canada (n= 9), United States (n= 7), or were multinational (n= 3). 
A total of 14 unique generic (n= 8) and disease-specific (n= 6) instruments were 
reported. The generic SF-36 (n= 18), and the disease-specific VEINES QoL/Sym (n= 12) 
were the most frequently used instruments. In general, the QoL of patients with 
VTE was significantly impaired in all domains – physical, social and psychological 
– compared with the general population, measured using both disease-specific and 
generic instruments. QoL scores tended to improve during follow-up with the great-
est improvement reported between 1–4 months following an initial event. Factors 
associated with poor QoL were identified: older age, obesity, female gender, comor-
bidities, and recurrent VTE events. Patients with PTS reported long-term worsening 
of QoL and functional disability compared with patients without PTS following 
an initial VTE event, with the impact on QoL increasing with severity of disease. 
However, in contrast to disease-specific QoL instruments, the impact of PTS on QoL 
was not consistently reported with generic questionnaires. cOnclusiOns: Initial 
VTE events and long-term complications, such as PTS, are significantly associated 
with reduced patients’ QoL in physical, psychological, and social domains. Disease-
specific measurements should be further developed to assess the long-term impact 
of VTE recurrence, PTS, and bleeding associated with anticoagulant use.
PCV123
an analysis Of eQ-5d Quality Of life data fOr a COst-effeCtiVeness 
analysis Of iVaBradine Plus standard Care Versus standard Care 
alOne in CHrOniC Hf
Griffiths A.1, Paracha N.2, Branscombe N.3, Cowie M.R.4, Sculpher M.2
1Research Economics, Solihull, UK, 2Oxford Outcomes, Oxford, UK, 3Les Laboratoires Servier, 
Suresnes, France, 4Imperial College London, London, UK
